Stockreport

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registratio [Read more]